Sales and Marketing Initiatives Continue to Drive Product Adoption

Highlights: Record fourth quarter revenue of EUR 7.0 million, up 44% year-over-year Full year revenue of EUR 22.3 million, up 10% year-over-year Approximately 3,400 Ablatherm-HIFU treatments in 2007; 15,000 cumulative treatments at 176 clinical sites Full year Ablatherm-HIFU RPP treatments increased 36% year-over-year Full year gross profit of EUR 9.2 million, up 10% year-over-year; gross profit margin of 41.3% Ablatherm-HIFU U.S. clinical trials continue to progress with successful launch of patient awareness program and fully funded by USD 20 million convertible debt raise Launch of integrated Sonolith I-Sys for the disintegration of urinary tract stones

Launch of Ablatherm-HIFU Patient Database '@-REGISTRY'

EDAP Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results LYON, France, March 12, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in high-intensity focused ultrasound (HIFU) for the treatment of prostate cancer, announced today details relating to

EDAP to Present At Cowen and Company 28th Annual Healthcare Conference LYON, France, March 10, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in high-intensity focused ultrasound (HIFU) for the treatment of prostate cancer, announced today that Marc Oczachowski, Chief

Web Site and Call Center to Aid in Patient Awareness of Phase II/III Clinical Trial for Prostate Cancer

EDAP's HIFU Technology Highlighted At Three Prestigious U.S. Medical Conferences LYON, France, Feb. 15, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that Ablatherm ® -HIFU was featured in presentations at three major U.S.

Journal of Endourology Highlights Ablatherm's Unique Sustainable Long-Term Clinical Data Ablatherm's Superior Safety and Efficacy Confirmed

EDAP TMS SA to Present at Roth 20th Annual OC Growth Stock Conference LYON, France, Feb. 13, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in high-intensity focused ultrasound (HIFU) for the treatment of prostate cancer, announced today that Marc Oczachowski, Chief Executive

Dr. Andrew Weil on Ablatherm-HIFU We are proud to announce that Dr. Andrew Weil, a well-known physician and author, recently spoke of the benefits associated with Ablatherm-HIFU minimally invasive, robotized technology. Please click on the below link to view Dr.